{
    "id": 27463,
    "fullName": "H3-3A K28M",
    "impact": "missense",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "H3-3A K28M (also referred to as K27M) does not lie within any known functional domains of the H3-3a protein (UniProt.org). K28M results in decreased H3K27 (K28) di-and trimethylation and inhibition of PRC2 methyltransferase activity, and leads to altered gene expression and increased proliferation in cultured cells (PMID: 23603901, PMID: 23539183, PMID: 28522693).",
            "references": [
                {
                    "id": 10739,
                    "pubMedId": 28522693,
                    "title": "Histone H3.3K27M Represses p16 to Accelerate Gliomagenesis in a Murine Model of DIPG.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28522693"
                },
                {
                    "id": 10736,
                    "pubMedId": 23603901,
                    "title": "The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23603901"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 10737,
                    "pubMedId": 23539183,
                    "title": "Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23539183"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 3020,
        "geneSymbol": "H3-3A",
        "terms": [
            "H3-3A",
            "H3-3B",
            "H3.3A",
            "H3F3",
            "H3F3A"
        ]
    },
    "variant": "K28M",
    "createDate": "02/06/2018",
    "updateDate": "12/11/2019",
    "referenceTranscriptCoordinates": {
        "id": 130843,
        "transcript": "NM_002107",
        "gDna": "chr1:g.226064434A>T",
        "cDna": "c.83A>T",
        "protein": "p.K28M",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 21181,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, H3.3K27M peptide vaccine combined with poly ICLC treatment was well tolerated, and resulted in an overall survival of 40% (n=19) at 12 months in patients with diffuse intrinsic pontine glioma (DIPG) harboring H3.3 K28M (also referred to as H3.3 K27M) (Neuro-Oncology, Vol.21, suppl_6, Abs nr: PDCT-17 (LTBK-11)).",
            "molecularProfile": {
                "id": 28928,
                "profileName": "H3-3A K28M"
            },
            "therapy": {
                "id": 9586,
                "therapyName": "H3.3K27M peptide vaccine + Poly ICLC",
                "synonyms": null
            },
            "indication": {
                "id": 4202,
                "name": "brain stem glioma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18451,
                    "pubMedId": null,
                    "title": "H3.3K27M SPECIFIC PEPTIDE VACCINE COMBINED WITH POLY-ICLC FOR THE TREATMENT OF NEWLY DIAGNOSED HLA-A2+ H3.3K27M MIDLINE GLIOMAS",
                    "url": "https://academic.oup.com/neuro-oncology/article-abstract/21/Supplement_6/vi284/5637723?redirectedFrom=fulltext"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13408,
            "approvalStatus": "Guideline",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "H3-3A K28M (also referred to as K27M) is associated with adverse prognosis in adult and pediatric glioma patients (NCCN.org).",
            "molecularProfile": {
                "id": 28928,
                "profileName": "H3-3A K28M"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 3070,
                "name": "malignant glioma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19433,
            "approvalStatus": "Expanded access",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, ONC201 treatment in patients with diffuse intrinsic pontine glioma harboring either H3-3A K28M or H3C2 K28M (also referred to as K27M) resulted in a median progression-free survival of 14 weeks (15 weeks adults; 13 weeks for pediatric patients), a median overall survival of 17 weeks, and a complete response in one patient (n=18), and three patients remained progression-free during treatment for a median of 49.6 weeks (PMID: 31456142).",
            "molecularProfile": {
                "id": 28928,
                "profileName": "H3-3A K28M"
            },
            "therapy": {
                "id": 1687,
                "therapyName": "ONC201",
                "synonyms": null
            },
            "indication": {
                "id": 3070,
                "name": "malignant glioma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17018,
                    "pubMedId": 31456142,
                    "title": "Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31456142"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 19434,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a cell line from a patient with diffuse intrinsic pontine glioma harboring H3-3A K28M (also referred to as K27M) demonstrated decreased viability when treated with ONC201 in culture, and subsequent treatment of the patient with ONC201 led to stable tumor size and continued treatment for over 18 months (PMID: 31456142).",
            "molecularProfile": {
                "id": 28928,
                "profileName": "H3-3A K28M"
            },
            "therapy": {
                "id": 1687,
                "therapyName": "ONC201",
                "synonyms": null
            },
            "indication": {
                "id": 3070,
                "name": "malignant glioma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17018,
                    "pubMedId": 31456142,
                    "title": "Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31456142"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21182,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, H3.3K27M peptide vaccine combined with poly ICLC treatment was well tolerated, and resulted in an overall survival of 39% (n=10) at 12 months in patients with non-DIPG midline glioma, including spinal cord tumors, harboring H3.3 K28M (also referred to as H3.3 K27M) (Neuro-Oncology, Vol.21, suppl_6, Abs nr: PDCT-17 (LTBK-11)).",
            "molecularProfile": {
                "id": 28928,
                "profileName": "H3-3A K28M"
            },
            "therapy": {
                "id": 9586,
                "therapyName": "H3.3K27M peptide vaccine + Poly ICLC",
                "synonyms": null
            },
            "indication": {
                "id": 3070,
                "name": "malignant glioma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18451,
                    "pubMedId": null,
                    "title": "H3.3K27M SPECIFIC PEPTIDE VACCINE COMBINED WITH POLY-ICLC FOR THE TREATMENT OF NEWLY DIAGNOSED HLA-A2+ H3.3K27M MIDLINE GLIOMAS",
                    "url": "https://academic.oup.com/neuro-oncology/article-abstract/21/Supplement_6/vi284/5637723?redirectedFrom=fulltext"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20747,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with LDN212854 resulted in decreased proliferation and cell survival in a diffuse intrinsic pontine glioma (DIPG) cell line harboring ACVR1 R206H and H3-3A K28M (H3.3 K27M) in culture (PMID: 30833574).",
            "molecularProfile": {
                "id": 35325,
                "profileName": "ACVR1 R206H H3-3A K28M"
            },
            "therapy": {
                "id": 9440,
                "therapyName": "LDN212854",
                "synonyms": null
            },
            "indication": {
                "id": 4202,
                "name": "brain stem glioma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18014,
                    "pubMedId": 30833574,
                    "title": "ACVR1 R206H cooperates with H3.1K27M in promoting diffuse intrinsic pontine glioma pathogenesis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30833574"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 28928,
            "profileName": "H3-3A K28M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35325,
            "profileName": "ACVR1 R206H H3-3A K28M",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 130843,
            "transcript": "NM_002107",
            "gDna": "chr1:g.226064434A>T",
            "cDna": "c.83A>T",
            "protein": "p.K28M",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}